Results 91 to 100 of about 22,199 (155)

Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in the Netherlands. [PDF]

Nephrol Dial Transplant
Deesker LJ, Franssen CFM, Dorresteijn E, van de Kar NCAJ, Nurmohamed SA, Severs D, Garrelfs SF, Pisters-van Roy AAMG, Hollak CEM, Groothoff JW.   +9 more
europepmc   +1 more source

Enhancing diagnostic efficiency of pyrazinamide resistance in <i>Mycobacterium tuberculosis</i> via modified MGIT assay and genotypic correlation. [PDF]

Curr Res Microb Sci
Rajendran A, Refaya AK, Subramanyam B, Karunaianantham R, RaviKumar D, Haribabu H, Gopalaswamy R, Golla R, Senthildevi V, Gomathi NS, Shanmugam S, Palaniyandi K.   +11 more
europepmc   +1 more source

Enhancing translational research impact through collaborative process innovation. [PDF]

J Clin Transl Sci
Palm ME, Phares S, Hirsch G.
europepmc   +1 more source

Antibodies to watch in 2026. [PDF]

MAbs
Crescioli S, Kaplon H, Chenoweth A, Hsu YS, Pinto K, Kapoor V, Reichert JM.   +6 more
europepmc   +1 more source

Celebrating the 40-year milestone: NF-ĸB in oncoimmunity. [PDF]

Cancer Lett
Alipourgivi F, Lu T.
europepmc   +1 more source

Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage? [PDF]

Indian J Crit Care Med
Chanchalani G.
europepmc   +1 more source

Structure-activity landscape of Nurr1 (NR4A2) modulators: medicinal chemistry strategies for neurodegenerative disease intervention. [PDF]

RSC Med Chem
Jaidka S, Kumar A, Singh TG, Bhatia R, Singh RK.   +4 more
europepmc   +1 more source

Visual Research of Global Orphan Drug from a Bibliometric Perspective. [PDF]

Drug Des Devel Ther
Wen X, Jin G, Wu C.
europepmc   +1 more source

Pharmaceutical governance system for costly drugs through human rights due diligence. [PDF]

BMJ
Lemmens T, Ghimire KM, Perehudoff K, Kohler JC, Low E, Persaud N.   +5 more
europepmc   +1 more source

Longitudinal Descriptive Analysis of Dynamic Changes in Safety Concerns in Japanese Risk Management Plans for Medicinal Products Over 8 Years After Approval. [PDF]

Ther Innov Regul Sci
Ishiguro C, Sazawa M, Nonaka T.
europepmc   +1 more source